falsefalse

Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 14

Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

Panelists briefly discuss the results of studies evaluating additional bispecific regimens in the later-stage relapsed/refractory multiple myeloma space, including cevostamab, ABBV-383 plus daratumumab-dexamethasone (Dd), and linvoseltamab in the LINKER-MM1 trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
    EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
    EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
    EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
    EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM
    EP. 6: Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM
    EP. 7: Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM
    EP. 8: Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4
    EP. 9: CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial
    EP. 10: Weighing CAR T Toxicity Profiles in Early R/R MM
    EP. 11: The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma
    EP. 12: Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma
    EP. 13: Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
    Now Viewing
    EP. 14: Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma
    EP. 15: Future Treatment Considerations for Multiple Myeloma

    Video content above is prompted by the following:

    • Briefly discuss results from the following studies, evaluating additional bispecific regimens in the later-stage R/R MM space.
    • Cevostamab in R/R MM:
    • ABBV-383-Dd in R/R MM:
    • Linvoseltamab in R/R MM in LINKER-MM1

    Related Content:

    Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory ClinicalVideo SeriesMultiple MyelomaOncLive Peer Exchange®
    Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma
    Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma
    Dr Dholaria on the Rationale for Investigating P-BCMA-ALLO1 in R/R Myeloma
    x